NVAX
Novavax, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.22
−1.16%Aug 28, 2026, 12:30 UTC
Novavax's partners received approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine formulation for the 2026-2027 vaccination season in the U.S., EU, and Japan.
Source:Aug 6, 2026, 12:00 UTC
Novavax reported total revenue of $57 million for the second quarter of 2026 and raised its full-year 2026 revenue framework and improved GAAP combined R&D and SG&A expense guidance by $10 million at the midpoint.
Jul 19, 2026, 15:52 UTC
Jianyi Biotechnology (a subsidiary of Shengde Group) signed a formal cooperation agreement with Polish CDMO company Mabion S.A. to jointly develop antibody-drug conjugates (ADCs) and target the European CDMO market.
Source: